MeiraGTx Holdings plc
450 East 29th Street
14th Floor
New York, NY 10016
United States
646 860 7985
https://meiragtx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 402
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Alexandria Forbes Ph.D. | CEO, President & Director | 2.89M | 無 | 1965 |
| Mr. Richard Brian Giroux B.A. | COO & CFO | 2.14M | 無 | 1973 |
| Dr. Stuart Naylor Ph.D. | Chief Development Officer | 1.06M | 無 | 1963 |
| Mr. Robert J. Wollin J.D. | General Counsel & Secretary | 無 | 無 | 1976 |
| Dr. Michel Michaelides M.D. | Head of Clinical Ophthalmology | 無 | 無 | 無 |
| Ms. Christine Elise Sheehy | Senior Vice President of Global Integration | 無 | 無 | 1968 |
| Mr. Tim Randall | Senior Vice President of Risk & Internal Controls | 無 | 無 | 無 |
| Dr. Alastair Leighton Ph.D. | Senior Vice President of Manufacturing & Supply Chain | 無 | 無 | 無 |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer | 1.1M | 無 | 1963 |
描述
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
公司管治
截至 2024年5月1日 止，MeiraGTx Holdings plc 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：4；董事會：4；股東權利：7；現金賠償：9。
